A detailed history of Price T Rowe Associates Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 438,259 shares of KRYS stock, worth $70.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
438,259
Previous 600,145 26.97%
Holding current value
$70.5 Million
Previous $110 Million 27.61%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$174.7 - $213.66 $28.3 Million - $34.6 Million
-161,886 Reduced 26.97%
438,259 $79.8 Million
Q2 2024

Aug 14, 2024

SELL
$153.12 - $183.64 $8.95 Million - $10.7 Million
-58,473 Reduced 8.88%
600,145 $110 Million
Q1 2024

May 15, 2024

BUY
$108.01 - $179.35 $25 Million - $41.5 Million
231,255 Added 54.11%
658,618 $117 Million
Q4 2023

Feb 14, 2024

BUY
$96.0 - $128.29 $16.4 Million - $22 Million
171,157 Added 66.8%
427,363 $53 Million
Q3 2023

Nov 14, 2023

SELL
$108.51 - $130.22 $7.46 Million - $8.95 Million
-68,741 Reduced 21.15%
256,206 $29.7 Million
Q2 2023

Aug 14, 2023

BUY
$78.48 - $130.32 $24.7 Million - $41 Million
314,337 Added 2962.65%
324,947 $38.2 Million
Q1 2023

May 15, 2023

BUY
$72.39 - $84.27 $49,804 - $57,977
688 Added 6.93%
10,610 $850,000
Q4 2022

Feb 14, 2023

SELL
$63.14 - $79.9 $17,174 - $21,732
-272 Reduced 2.67%
9,922 $786,000
Q3 2022

Nov 14, 2022

BUY
$64.85 - $82.4 $208,687 - $265,163
3,218 Added 46.13%
10,194 $711,000
Q2 2022

Aug 15, 2022

SELL
$48.93 - $73.47 $122,178 - $183,454
-2,497 Reduced 26.36%
6,976 $458,000
Q1 2022

May 16, 2022

BUY
$51.99 - $72.11 $71,122 - $98,646
1,368 Added 16.88%
9,473 $630,000
Q4 2021

Feb 14, 2022

BUY
$39.81 - $88.24 $154,701 - $342,900
3,886 Added 92.11%
8,105 $567,000
Q2 2021

Aug 16, 2021

BUY
$62.14 - $81.82 $31,070 - $40,910
500 Added 13.44%
4,219 $287,000
Q1 2021

May 17, 2021

BUY
$59.42 - $85.46 $220,982 - $317,825
3,719 New
3,719 $287,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.13B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.